Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 08/24 05:31:06 pm
78.45 CHF   -0.19%
07:16a NOVARTIS : announces positive phase III results showing efficacy of ..
08/24 NOVARTIS AG (NY : NVS) Licenses LGT209 To Cyon Therapeutics, Inc., T..
08/23 NOVARTIS : Kenya Red Cross Society and Novartis Join Forces
News SummaryMost relevantAll newsSector news 

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
04/25/2012 | 01:16am CEST

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
07:16a NOVARTIS : announces positive phase III results showing efficacy of BAF312 in pa..
08/24 NOVARTIS AG (NYSE : NVS) Licenses LGT209 To Cyon Therapeutics, Inc., Teams Up Wi..
08/24 NOVARTIS : Today's Cartoon (August 24 2016)
08/23 NOVARTIS : Kenya Red Cross Society and Novartis Join Forces
08/22DJEli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/19 NOVARTIS : Alcon Research Assigned Patent
08/18 NOVARTIS : New drugs hope to fight neglected tropical diseases
08/18 JACOBS ENGINEERING : Awarded Contract for Novartis Biotechnology Center Expansio..
08/18 NOVARTIS : Patent Issued for Combination Therapy (USPTO 9408847)
08/18 NOVARTIS : NICE says Novartis' and Janssen's cancer drugs are not cost effective
More news
Sector news : Pharmaceuticals - NEC
08/24DJPFIZER : Buys Part of AstraZeneca's Antibiotics Business -- 2nd Update
08/24DJASTRAZENECA : Sells Part of its Antibiotics Business to Pfizer -- Update
08/24DJPfizer Buys Part of AstraZeneca's Antibiotics Business
08/24DJASTRAZENECA : Sells Part of Antibiotics Business to Pfizer for Up to $1.575 Bill..
08/23DJU.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/23 Who's Next After Medivation?
08/22 Finding And Owning The Best Businesses In The World
08/21 13 Buys And 7 Sells From The Wide-Moat Universe
08/19 Play Oncology To Play M&A In Big Pharma?
08/18 5 Stocks That Beat The Market In A Crash
Financials ($)
Sales 2016 48 839 M
EBIT 2016 11 381 M
Net income 2016 7 463 M
Debt 2016 14 751 M
Yield 2016 3,50%
P/E ratio 2016 23,72
P/E ratio 2017 21,59
EV / Sales 2016 4,68x
EV / Sales 2017 4,55x
Capitalization 213 882 M
More Financials
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 89,5 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-9.45%213 882
JOHNSON & JOHNSON15.57%324 776
ROCHE HOLDING LTD.-11.47%217 652
PFIZER INC.7.87%211 206
MERCK & CO., INC.18.76%173 462
More Results